Announcements Trials
Browse Landscape

Phase

Phase 1 4

Status

Completed 4Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 67Breast 41Plasma cell 19Lymphoid 14Sarcoma 5Other hematologic neoplasm 5Tumor-Agnostic 4Genitourinary 4Dermatologic 4Other solid neoplasm 3Thoracic 2NET 1Head & Neck 1Gastrointestinal 1Endocrine 1Classical hematology 1CNS 1

Conditions

Neoplasms 3Neoplasm Metastasis 1Carcinoma 1

Interventions

Paclitaxel 57Gemcitabine 51Carboplatin 51Surveys and Questionnaires 48Docetaxel 37Bevacizumab 37pembrolizumab 33Nivolumab 29Cisplatin 28Fluorouracil 24Capecitabine 23Irinotecan 22Erlotinib Hydrochloride 22Sorafenib 20Leucovorin 19Afatinib 19Radiotherapy 18Pemetrexed 18Oxaliplatin 17Trastuzumab 16Ipilimumab 15regorafenib 14Blood Specimen Collection 14130-nm albumin-bound paclitaxel 14olaparib 13Interviews as Topic 13Cetuximab 13Albumin-Bound Paclitaxel 13atezolizumab 12Sunitinib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × liposomal doxorubicin × Tumor-Agnostic × Clear all
NCT02483247 2023-11-14

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

Sumitomo Pharma America, Inc.

Phase 1 Completed
165 enrolled
Tumor-Agnostic

Neoplasms

NCT00761644 2019-04-11

Doxil, Bevacizumab and Temsirolimus Trial

M.D. Anderson Cancer Center

Phase 1 Completed
200 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT01455532 2014-10-22

A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors

Sanofi

Phase 1 Completed
59 enrolled
Tumor-Agnostic

Neoplasms

NCT00183742 2014-05-22

Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere)

University of Southern California

Phase 1 Completed
35 enrolled
Tumor-Agnostic

Carcinoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡